GlassScriptPhysician profile
Myra Pieratt
NPI 1396700308
$7,053.56
in general payments reported to CMS, 2019-2025
38 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,701 · 2022: $1,183 · 2023: $1,295 · 2024: $1,285 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,170.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,241.67 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,181.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,003.77 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.62 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $468.88 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $459.08 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $246.74 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.27 | 2021-2025 | |
| Amgen INC. | $209.80 | 2021-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $182.40 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $153.47 | 2021-2025 | Spravato |
| Merck Sharp & Dohme LLC | $114.23 | 2021-2025 | Lagevrio, Dificid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.12 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $78.48 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $77.25 | 2021-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $73.54 | 2024-2025 | Heplisav-B |
| Arbor Pharmaceuticals, INC. | $68.08 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.58 | 2021-2024 | Trintellix |
| Xeris Pharmaceuticals, INC. | $61.00 | 2022-2024 | Gvoke Hypopen |
| Abbott Laboratories | $53.81 | 2021-2023 | Freestyle Libre |
| Esperion Therapeutics, INC. | $52.19 | 2021-2023 | Nexletol |
| Axsome Therapeutics, INC. | $41.74 | 2023 | Auvelity |
| Ibsa Pharma INC. | $38.02 | 2022 | |
| Edwards Lifesciences Corporation | $35.96 | 2025 | Sapien 3 Ultra Resilia |
| Vanda Pharmaceuticals INC. | $32.04 | 2025 | Hetlioz, Fanapt |
| Exact Sciences Corporation | $31.39 | 2025 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $31.17 | 2024-2025 | Edarbi |
| Kowa Pharmaceuticals America, INC. | $27.12 | 2021-2025 | Zoryve |
| Cipher Pharmaceuticals US LLC | $25.57 | 2025 | Natroba, Spinosad |
| Phathom Pharmaceuticals, INC. | $23.71 | 2025 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $23.23 | 2023 | |
| Idorsia Pharmaceuticals US INC | $18.94 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $18.37 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $16.11 | 2023 | Eliquis |
| Dexcom, INC. | $14.29 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $13.53 | 2024 | Korlym |
| Inogen, INC. | $13.27 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myra Pieratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.